Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS).

Détails

ID Serval
serval:BIB_F0595C8CBCDD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS).
Périodique
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Auteur⸱e⸱s
Lefaucheur J.P., Antal A., Ayache S.S., Benninger D.H., Brunelin J., Cogiamanian F., Cotelli M., De Ridder D., Ferrucci R., Langguth B., Marangolo P., Mylius V., Nitsche M.A., Padberg F., Palm U., Poulet E., Priori A., Rossi S., Schecklmann M., Vanneste S., Ziemann U., Garcia-Larrea L., Paulus W.
ISSN
1872-8952 (Electronic)
ISSN-L
1388-2457
Statut éditorial
Publié
Date de publication
01/2017
Peer-reviewed
Oui
Volume
128
Numéro
1
Pages
56-92
Langue
anglais
Notes
Publication types: Review ; Journal Article
Publication Status: ppublish
Résumé
A group of European experts was commissioned by the European Chapter of the International Federation of Clinical Neurophysiology to gather knowledge about the state of the art of the therapeutic use of transcranial direct current stimulation (tDCS) from studies published up until September 2016, regarding pain, Parkinson's disease, other movement disorders, motor stroke, poststroke aphasia, multiple sclerosis, epilepsy, consciousness disorders, Alzheimer's disease, tinnitus, depression, schizophrenia, and craving/addiction. The evidence-based analysis included only studies based on repeated tDCS sessions with sham tDCS control procedure; 25 patients or more having received active treatment was required for Class I, while a lower number of 10-24 patients was accepted for Class II studies. Current evidence does not allow making any recommendation of Level A (definite efficacy) for any indication. Level B recommendation (probable efficacy) is proposed for: (i) anodal tDCS of the left primary motor cortex (M1) (with right orbitofrontal cathode) in fibromyalgia; (ii) anodal tDCS of the left dorsolateral prefrontal cortex (DLPFC) (with right orbitofrontal cathode) in major depressive episode without drug resistance; (iii) anodal tDCS of the right DLPFC (with left DLPFC cathode) in addiction/craving. Level C recommendation (possible efficacy) is proposed for anodal tDCS of the left M1 (or contralateral to pain side, with right orbitofrontal cathode) in chronic lower limb neuropathic pain secondary to spinal cord lesion. Conversely, Level B recommendation (probable inefficacy) is conferred on the absence of clinical effects of: (i) anodal tDCS of the left temporal cortex (with right orbitofrontal cathode) in tinnitus; (ii) anodal tDCS of the left DLPFC (with right orbitofrontal cathode) in drug-resistant major depressive episode. It remains to be clarified whether the probable or possible therapeutic effects of tDCS are clinically meaningful and how to optimally perform tDCS in a therapeutic setting. In addition, the easy management and low cost of tDCS devices allow at home use by the patient, but this might raise ethical and legal concerns with regard to potential misuse or overuse. We must be careful to avoid inappropriate applications of this technique by ensuring rigorous training of the professionals and education of the patients.

Pubmed
Création de la notice
05/12/2016 22:41
Dernière modification de la notice
20/08/2019 17:18
Données d'usage